

September 30, 2026

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)
Contact: Richard Kincaid, Executive Officer CFO
(TEL: 03-6807-5937)

Notice Regarding Shipment Timing of Initial Order of Culture Supernatant Products to JENECELL

HEALIOS K.K. (“Healios”) is engaged in business activities aimed at developing and providing innovative therapies and products in the field of regenerative medicine. As part of these efforts, we are advancing the research, development, manufacturing, and sales of products based on somatic stem cell culture supernatant.

As previously announced on April 7, 2026 in “[Agreement with JENECELL to Supply Culture Supernatant](#)”, Healios entered into an Agreement with JENECELL (Head office: 397 Seochodaero-ro #A-1907, Seocho-gu, Seoul, 06616, South Korea (<https://www.jenecell.com>); “JENECELL”) to supply culture supernatant products to be used as a raw material for cosmetics (the “Product”).

Product: Human (allogeneic) bone marrow-derived somatic stem cell culture supernatant (HLSI071)

The shipment of the Product for the initial order, worth approximately 144 million yen, was originally scheduled for the third quarter (July to September) of the fiscal year ending December 2026. Healios hereby announces that the shipment is now scheduled for October 2026. This change in shipment timing is due to a delay in logistics procedures for the overseas transport of the Product, which has already been manufactured and arranged for shipment, and is not attributable to any issue in the manufacturing of the Product. Healios will work closely with JENECELL to proceed with preparations for shipment as promptly as possible.

Future Outlook

Revenue from this shipment will be recognized upon completion of the shipment, and is now expected to be recognized in the fourth quarter of the fiscal year ending December 2026, rather than in the third quarter as originally anticipated. Healios will make a further announcement upon completion of the shipment. If any matters that should be disclosed arise in the future, we will announce them promptly.

About JENECELL:

JENECELL is a South Korean subsidiary of Alfresa Corporation, a subsidiary of Alfresa Holdings Corporation—the leading pharmaceutical wholesaler in Japan—and develops innovative products utilizing cutting-edge technology across a wide range of fields, including stem cell-based pharmaceuticals, medical devices, and cosmetics. In particular, we are driving the development of high-performance skincare products through our premium cosmetics business, which is based on stem cell-conditioned media (MSC-CM). Building on strategic partnerships with promising South Korean biotech and healthcare companies, we are actively pursuing an open innovation strategy that includes both In and Out business initiatives as well as mergers and acquisitions.

<https://www.jenecell.com>

About Healios:

HEALIOS K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing HLCM051(invimestrocel), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. HLCM051 has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance HLCM051 on a global basis for ARDS, trauma, and ischemic stroke. In the iPSC regenerative medicine field, Healios has developed HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-modification. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process. The development of AKT-01/HLCN061 is currently being led by our development partner, Akatsuki Therapeutics, Inc., in preparation for the initiation of clinical trials. Healios has also established a proprietary, gene-edited "universal donor" induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).

<https://www.healios.co.jp/en>